* The study focuses on the risks associated with severe infections in large B-cell lymphoma patients post CAR-T therapy, specifically examining how disease burden and existing complications influence these risks.
* Findings suggest that a higher disease burden post-therapy increases infection risk, particularly in patients with multiple infections during treatments like ICANS; the study introduces the concept of "CAR-T cold sepsis" and recommends a strategy for better clinician awareness to minimize non-relapse mortality.